Clinical trials: Influenza Virus Infection
SARS-CoV-2, Influenza
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS…
- Trial name
- NCT06097273
- Testing
- mRNA-1083, Influenza Vaccine, COVID-19 Vaccine
- Where
- 146 sites in United States
- Volunteers
- 8,061 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders
This was a randomized, laboratory-blinded study in healthy male and non-pregnant female designed to investigate the safety, reactogenicity, and immunogenicity of an inactivated influenza H1N1 vaccine (AdimFlu-S).
- Trial name
- NCT01003145
- Testing
- Influenza A (H1N1) 2009 monovalent vaccine, inactivated
- Where
- 3 sites in Taiwan
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Virus Diseases, RNA Virus Infections
Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults
The primary objective is to assess the safety and tolerability of two consecutive doses of plant-based H5 VLP, (H5N1) pandemic influenza vaccine combined with Alhydrogel®, given 21 days apart, at three dose levels: 5µg, 10µg and…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT00984945
- Testing
- H5 VLP pandemic influenza vaccine 5 µg, H5 VLP pandemic influenza vaccine 10 µg, H5 VLP pandemic influenza vaccine 20 µg
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Medicago
COVID -19, Influenza A
Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings
The Metrix Respiratory Panel Test will be evaluated for use in Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus
- Trial name
- NCT07217639
- Testing
- Aptitude Medical Systems Respiratory Panel Test
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Aptitude Medical Systems
Influenza
Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Anhui/1/2013 (H7N9) administered at 3 dose levels in adjuvanted (SE) rHA formulations…
- Trial name
- PSC26 (NCT02464163)
- Testing
- Panblok, rHA adjuvant
- Where
- 9 sites in United States
- Volunteers
- 407 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza A H3N2, Influenza A H1N1
Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
Influenza, or the flu, is an infectious respiratory disease that can range in severity from mild to severe to even death. This study aims to evaluate a treatment for people who are hospitalized with the flu.
- Trial name
- NCT03315104
- Testing
- FLU-IGIV
- Where
- 55 sites in United States, Canada and 2 more
- Volunteers
- 65 people
- Sponsor
- Emergent BioSolutions
Influenza
Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine
To observe and to describe the safety during Days 0 to 21 following injection of the 2004-2005 formulation of the inactivated, split-virion influenza vaccine Fluzone® in subjects aged 18-59 years and subjects aged ≥ 60 years.
- Trial name
- NCT00831987
- Testing
- Fluzone®: Influenza virus vaccine 2004-2005 formulation
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age
Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian virus. Prevention and control of a pandemic will depend on the rapid production and worldwide distribution of specific pandemic vaccines.
- Trial name
- NCT00309647
- Testing
- Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine, Influenza Monovalent Whole virus (H5N1)
- Where
- 9 sites in Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2015/2016 Quadrivalent Influenza Vaccine…
- Trial name
- NCT02545543
- Testing
- Seqirus QIV, Comparator QIV
- Where
- 32 sites in United States
- Volunteers
- 2,278 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling
Multicapillary Ion mobility spectrometry of nasal air aspirates shall be investigated as screening tool for the detection of Influenza and SARS-CoV-2- infection.
- Trial name
- NCT04282135
- Testing
- MCC IMS
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- Klinikum Bayreuth GmbH
Influenza
Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate
The purpose of this study is to evaluate the immunogenicity and the safety of a second vaccination with candidate vaccine compared to Fluarix™ administered intramuscularly in elderly aged 60 years and above
- Trial name
- NCT00385840
- Testing
- Influenza Vaccine GSK1247446A, FluarixTM
- Where
- 4 sites in Norway
- Volunteers
- 678 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Virus Diseases, RNA Virus Infections
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
This Phase 3 study is intended to assess the clinical lot-to-lot consistency in manufacturing by evaluating and comparing the immunogenicity of three consecutively manufactured lots of the Quadrivalent Virus-Like Particles (VLP)…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Infections, Respiratory Tract Disease
- Trial name
- NCT03321968
- Testing
- Quadrivalent VLP Influenza Vaccine
- Where
- 10 sites in Canada
- Volunteers
- 1,202 people, healthy volunteers welcome
- Sponsor
- Medicago
Influenza
Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects
Based on pre-clinical trial data and principle of GCP, the objective of phase I clinical trial is to evaluate safety and immunogenicity of Pan-flu vaccine, an inactivated whole virion H5N1 vaccine with aluminium hydroxide…
- Trial name
- NCT00356798
- Testing
- an inactivated whole virion H5N1 vaccine, adjuvanted
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Common Cold
Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine
Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the drug combination of Ibuprofen/Loratadine versus Ibuprofen versus Loratadine as…
- Trial name
- NCT06531707
- Testing
- Ibuprofen + Loratadine fixed dose, Ibuprofen, Loratadine
- Where
- Mexico
- Volunteers
- 177 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Influenza
Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry
The purpose of this pregnancy registry study is to detect and describe abnormal pregnancy outcomes in women intentionally or unintentionally vaccinated with any of GlaxoSmithKline (GSK) Biologicals' seasonal Inactivated Influenza…
- Trial name
- NCT02148211
- Testing
- Data collection
- Where
- United States
- Volunteers
- 507 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Influenza Challenge Study in Healthy Volunteers
A study to determine the infectious titre of an Influenza A (H1N1) (A/New Caledonia/20/99) virus for use in other Influenza challenge studies for the development of Influenza vaccines, antiviral agents and to better understand…
- Trial name
- NCT02746211
- Testing
- High Titre Influenza virus, Medium - High Influenza virus, Medium Low Titre Influenza virus
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hvivo
COVID-19
Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
This is a multicenter, observer-blind, randomized, controlled phase 3 study to evaluate the immunogenicity, reactogenicity, and safety of an investigational self-amplifying RNA COVID-19 vaccine (ARCT-2303) administered…
- Trial name
- NCT06279871
- Testing
- ARCT-2303, Influenza vaccine, Influenza vaccine, adjuvanted
- Where
- 29 sites in Australia, Costa Rica and 2 more
- Volunteers
- 1,514 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Influenza
Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after…
- Trial name
- NCT00529516
- Testing
- Fluarix, GSK Biologicals Influenza Vaccine GSK576389A
- Where
- 29 sites in United States, Belgium and 2 more
- Volunteers
- 1,252 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
The purpose of this study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic and safe when given to adults aged >=18 years.
- Trial name
- NCT00719043
- Testing
- A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- Where
- 13 sites in United States, Canada
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks
A multicenter, observational study to evaluate the safety of Euforvac-Hib vaccine for active primary immunization against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenza type B in infants.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT02257645
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.